LIBLICENSE-L Archives

LibLicense-L Discussion Forum

LIBLICENSE-L@LISTSERV.CRL.EDU

Options: Use Forum View

Use Monospaced Font
Show Text Part by Default
Show All Mail Headers

Message: [<< First] [< Prev] [Next >] [Last >>]
Topic: [<< First] [< Prev] [Next >] [Last >>]
Author: [<< First] [< Prev] [Next >] [Last >>]

Print Reply
Subject:
From:
LIBLICENSE <[log in to unmask]>
Reply To:
LibLicense-L Discussion Forum <[log in to unmask]>
Date:
Wed, 31 Jul 2013 17:29:31 -0400
Content-Type:
text/plain
Parts/Attachments:
text/plain (37 lines)
From: "Osterbur, David L." <[log in to unmask]>
Date: Wed, 31 Jul 2013 09:28:58 -0400

Elsevier is an appropriate comparison. Look at the price of American
Journal of Kidney Disease from 2008 to 2009. Elsevier took over
publication that year from the National Kidney Foundation. Our price
for the journal increased 450%.

David L. Osterbur, Ph.D.
Director of Access and Public Services
Countway Library of Medicine
Harvard Medical School
Boston, MA   02115
[log in to unmask]


-----Original Message-----
From: Rick Anderson <[log in to unmask]>
Date: Tue, 30 Jul 2013 02:32:09 +0000

>Did APS costs increase 35%? Did the CPI JUMP and I didnšt hear about
>it?  Is there some phantasmagorical Elsevier level reasoning
>transported via time warp from the 1980šs that justifies this for my
>institution ? Has APS been reading the news about funding in state
>institutions?

I'm not sure Elsevier is actually the right point of comparison here
-- to my (limited) knowledge, they've never presented any of their
customers with a sudden 35% price increase. The pricing behavior that
Chuck is describing sounds much more like that of our non-profit
friends at the American Chemical Society.

---
Rick Anderson
Interim Dean, J. Willard Marriott Library University of Utah
[log in to unmask]

ATOM RSS1 RSS2